Global Anti-Hypertensive Drugs Market Research Report- Forecast to 2022

Overview
The global antihypertensive drugs market size is anticipated to reach USD 41,123.2 million by 2023, as per the findings of Market Research Future (MRFR). Antihypertensive drugs are indicated by reputed clinicians for the management of hypertension or elevated blood pressure. Long-term high blood pressure is one of the leading causes of heart failure, stroke, peripheral vascular disease, chronic kidney disease, and others. High prevalence of hypertension is the primary driver of the antihypertensive drugs market.

Awareness campaigns by non-profit and governmental organizations is likely to work in favor of the market. For instance, the Pulmonary Hypertension Association (PHA) offers education programs and has a strong support network which offers patients with right treatment information. Rising prevalence of chronic diseases is fueling the demand for antihypertensive drugs. In addition, the entry of generics which has brought down patient costs is projected to bode well for the market over the forecast period (2018-2023). The market can experience 2.67% CAGR over the forecast period owing to new forms of antihypertensive therapy options.

Report Overview
The report analyzes factors affecting the global antihypertensive drugs market by taking a microscopic view of various trends. It predicts the market size and volume based on first-class research undertaken by subject matter experts or research analysts at MRFR. The scope of the report covers drivers, restraints, opportunities, and threats engulfing the market. With easy-to-understand segmentation of the market by therapeutic class, type, distribution channel, and region, the market forecasts predictions based on historical and upcoming trends. Key players operating in the market are profiled coupled with their respective strategies for sustaining the market competition.

Segmentation
Various therapeutic classes of antihypertensive drugs discussed are calcium channel blockers, beta-adrenergic blockers, renin inhibitors, angiotensin-converting enzyme (ACE) inhibitors, vasodilators, diuretics, angiotensin II receptor blockers (ARBs), and others. By type, the antihypertensive drugs market is segmented into primary and secondary hypertension. Distribution channels covered in the market report include e-commerce websites and online drug stores, hospital pharmacy, retail pharmacy, and others.

Regional Analysis
Region-wise, the global antihypertensive drugs market covers Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas accounted for the largest market share in 2017, followed by Europe, APAC, and MEA. It can dominate the global market till 2023 due to high awareness levels of hypertension and the large patient pool. In addition, guidelines outlined by organizations for creating awareness of hypertension due to the high risk posed by cardiovascular diseases.
Competitive Analysis

Key players in the antihypertensive drugs market are Sanofi S.A. (France), Novartis AG (Switzerland), AstraZeneca (U.K.), Daiichi Sankyo Company, Ltd. (Japan), Boehringer Ingelheim GmbH (Germany), Takeda Pharmaceutical Company (Japan), Merck KGaA (Germany), Johnson & Johnson Services, Inc. (U.S.), Bayer AG (Germany), Pfizer, Inc. (U.S.), and United Therapeutics Corporation (U.S.). The market is characterized by expiry of various patented drugs and entry of generics. Players are taking measures to regain their lost standing by investing in research and development and launch of new products.

Research Methodology

Primary and secondary research have been undertaken to profile the global gas and liquid argon market and present to readers an accurate overview of the intricacies of the market. Primary research channels used by MRFR analysts include leading players in the global gas and liquid argon market, whereas secondary research is conducted through reliable sources such as SEC filings, whitepapers, and press releases. Every precaution is taken to ensure the accuracy of the data presented in the report.

Analysis Period

- Base Year - 2017
- Projection Period - 2018 to 2023
- Market Valuation - USD Million

Therapeutic Class

- Calcium Channel Blockers
- Beta-adrenergic Blockers
- Renin Inhibitors
- ACE Inhibitors
- Vasodilators
- Diuretics
- ARBs
- Others

Type

- Primary Hypertension
- Secondary Hypertension

Distribution Channel

- E-commerce Websites & Online Drug Stores
- Retail Pharmacy
- Hospital Pharmacy
- Others

Region

- Americas
  - North America
    - The U.S.
    - Canada
  - Latin America
- Europe
  - Western Europe
    - Germany
    - The U.K.
    - France
    - Italy
    - Spain
    - Rest of Western Europe
  - Eastern Europe
- Asia Pacific (APAC)
  - China
  - Japan
  - India
  - Australia